Fondaparinux: an update on new study results.
Fondaparinux (Arixtra) is the first selective factor Xa inhibitor approved for use in thromboprophylaxis after orthopaedic surgery. New recently completed trials have also demonstrated the potential of fondaparinux in the prevention of venous thromboembolism (VTE) in other surgical and medical settings and in the treatment of established VTE. In the randomized double-blind PEGASUS study in high-risk abdominal surgery patients, fondaparinux reduced the incidence of VTE from 6.1% with dalteparin to 4.6% (odds ratio reduction = 25.8%, P = 0.14), without increasing the bleeding risk. In the randomized double-blind ARTEMIS trial in acutely ill medical patients, fondaparinux reduced the incidence of VTE from 10.5% with placebo to 5.6% (odds ratio reduction = 49.5%, P = 0.029), without increasing the bleeding risk; there was no pulmonary embolism in the fondaparinux group compared with five, all fatal, in the placebo group (P = 0.029). In the two MATISSE trials, both the efficacy and safety of once daily fondaparinux were at least as good as enoxaparin in the treatment of deep-vein thrombosis (MATISSE-DVT) and unfractionated heparin in the treatment of pulmonary embolism (MATISSE-PE). In patients with coronary artery disease, promising results were obtained in phase II trials and large phase III trials are ongoing. In conclusion, fondaparinux may further improve and simplify the prevention and treatment of thrombosis in a large range of medical and surgical settings.
Bauersachs
R M
RM
Vascular Medicine, Medical Department IV, Klinikum Darmstadt, Germany. bauersachs@em.uni-frankfurt.de
D000789:Angina, Unstable / Q000188:drug therapy; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D000990:Antithrombin III / Q000037:antagonists & inhibitors*; D000077425:Fondaparinux; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D011134:Polysaccharides / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
D000925:Anticoagulants; D011134:Polysaccharides; D000990:Antithrombin III; D000077425:Fondaparinux